港股异动 | 四环医药(0460.HK)涨4.7% 联营公司获得新增投资方增资
格隆汇8月20日丨四环医药(0460.HK)现报0.88港元,涨幅4.76%,最新总市值83.3亿港元。公司19日公告称,广东冠润股权投资合伙企业(有限合伙)和南靖惠及股权投资合伙企业(有限合伙)对集团联营公司北京锐业进行增资。完成后,北京锐业的整体估值为人民币29亿元,集团持股比例为40.966%,两位投资方共占6.896%。北京锐业目前具有非PVC粉液双室袋即配型输液领先技术。已经获得该剂型头孢他啶、头孢呋辛、头孢地嗪多个品种和规格的生产批件。此次增资,体现了投资方对北京锐业双室袋业务的认可,以及对头孢他啶、头孢呋辛、头孢地嗪三个抗生素产品广阔市场前景的期待。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.